With the much-debated exception of the modestly reduced acquisition reported for the
RV144 efficacy trial, HIV-1 vaccines have not protected humans against infection, and a …

SARS-CoV-2 is a novel betacoronavirus that caused coronavirus disease 2019 and has
resulted in millions of deaths worldwide. Novel coronavirus infections in humans have …

The commensal microflora provides a repertoire of antigens that illicit mucosal antibodies. In
some cases, these antibodies can cross-react with host proteins, inducing autoimmunity, or …

Decrypting the B cell ontogeny of HIV-1 broadly neutralizing antibodies (bNAbs) is
paramount for vaccine design. Here, we characterized IgA and IgG bNAbs of three distinct B …

Vaccine-elicited humoral immune responses comprise an array of antibody forms and
specificities, with only a fraction contributing to protective host immunity. Elucidation of …

ABSTRACT HIV Vaccine Trials Network (HVTN) 505 was a phase 2b efficacy trial of a
DNA/recombinant adenovirus 5 (rAd5) HIV vaccine regimen. Although the trial was stopped …

Humoral immune perturbations contribute to pathogenic outcomes in persons with HIV-1
infection (PWH). Gut barrier dysfunction in PWH is associated with microbial translocation …

Efficacious HIV-1 vaccination requires elicitation of long-lived antibody responses. However,
our understanding of how different vaccine types elicit durable antibody responses is …

Induction of persistent HIV-1 Envelope (Env) specific antibody (Ab) is a primary goal of HIV
vaccine strategies; however, it is unclear whether HIV Env immunization in humans induces …

Despite prolific efforts to characterize the antibody response to human immunodeficiency
virus type 1 (HIV-1) and hepatitis C virus (HCV) mono-infections, the response to chronic co …